Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Christopher John Halyk Insider Profile
4 Followers
Christopher John Halyk, Director at MediPharm Labs, holds 264.73K shares in MediPharm Labs (Ticker: MEDIF).
Christopher John Halyk has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Christopher John Halyk's holdings
Insider Roles
Director
Roles that Christopher John Halyk holds in companies
Most Profitable Insider Trade
The most profitable trade made by Christopher John Halyk
Christopher John Halyk's Trading History
List of latest transactions for each holding click on a transaction to see Christopher John Halyk's performance on stock
You May Also Like
Christopher John Halyk insider profile FAQ
What is the percentage of profitable transactions made by Christopher John Halyk?
The percentage of profitable transactions made by Christopher John Halyk is ―.
What is the average return per transaction made by Christopher John Halyk?
The average return per transaction made by Christopher John Halyk is ―.
What stocks does Christopher John Halyk hold?
Christopher John Halyk holds: MEDIF stocks.
What was Christopher John Halyk’s latest transaction?
Christopher John Halyk latest transaction was an Uninformative Sell of ―.
What was Christopher John Halyk's most profitable transaction?
Christopher John Halyk’s most profitable transaction was an Informative Buy of MEDIF stock on March 9, 2021. The return on the trade was -71.30%.
What is Christopher John Halyk's role in MediPharm Labs?
Christopher John Halyk's role in MediPharm Labs is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.